Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – Pipeline Forecast & Market Forecast in G8 Countries (2011 – 2020)

Description:

The acute lymphocytic/lymphoblastic leukemia therapeutics market has growth potential with increasing incidence rate of the disease across the globe.

The incidence of acute lymphocytic/lymphoblastic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic/lymphoblastic leukemia may also occur in adults. The acute lymphocytic/lymphoblastic leukemia market is segmented into two types - childhood acute lymphocytic/lymphoblastic leukemia and adult acute lymphocytic/lymphoblastic leukemia.

The acute lymphocytic/lymphoblastic leukemia therapeutics market primarily covers regimens and drugs (patented, off-patent, and pipeline). The growing acute lymphocytic/lymphoblastic leukemia incidence rate is an impetus for the growth of the market. This market is expected to grow at a CAGR of 4.0% from 2015 to 2020.

In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.).

In contrast to the growth of the market, the cost of therapies is majorly restraining the acute lymphocytic/lymphoblastic leukemia therapeutics market. In addition, patent expirations of some of the existing drugs in the market are also expected to limit the market growth during 2013 to 2020.

Market players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to November 2013.

Scope of the Report

Drug

- Existing Regimens/Drugs
  -- Hyper-CVAD Regimen
  -- CALGB 8811 Regimen
  -- Linker Regimen
  -- Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
  -- Oncaspar

- Pipeline Drugs (Phase III)
  -- Graspa
  -- Marqibo
  -- Inotuzumab Ozogamicin

Geography

- North America
  -- U.S.
  -- Canada

- Europe
  -- Germany
  -- France
  -- Italy
  -- Spain
  -- U.K.
Contents:

1 Introduction
   1.1 Objectives of The Study
   1.2 Report Description
   1.3 Markets Covered
   1.4 Stakeholders
   1.5 Research Methodology
      1.5.1 Market Size Estimation and Data Triangulation
      1.5.2 Market Estimation Model
      1.5.3 Key Data Points Taken From Secondary Sources
      1.5.4 Assumptions Made For This Report

2 Executive Summary

3 Market Overview
   3.1 Defining Leukemia
   3.2 Acute Lymphocytic Leukemia
      3.2.1 Risk Factors
      3.2.2 Stages/Risk Groups of Acute Lymphocytic Leukemia
         3.2.2.1 Childhood All
            3.2.2.1.1 Standard (LOW) Risk
            3.2.2.1.2 High Risk
            3.2.2.1.3 Recurrent
            3.2.2.2 Adult All
               3.2.2.2.1 Untreated Adult All
               3.2.2.2.2 Adult All in Remission
               3.2.2.2.3 Recurrent Adult All
         3.2.3 Diagnosis
            3.2.3.1 Biopsy and Bone Marrow Aspiration
            3.2.3.2 Complete Blood Count (CBC) and Differential
            3.2.3.3 Presence of Philadelphia Chromosome
            3.2.3.4 Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis
            3.2.3.5 Immunophenotyping Or Phenotyping By Flow Cytometry
            3.2.3.6 Polymerase Chain Reaction (PCR)
         3.2.4 Leukemia Prevalence
         3.2.5 Incidence & Mortality
   3.3 Market Structure
      3.3.1 Key Therapies
         3.3.1.1 Chemotherapy
         3.3.1.2 Stem Cell/Bone Marrow Transplant
         3.3.1.3 Radiation Therapy

4 Acute Lymphocytic Leukemia Market Dynamics
   4.1 Market Overview
   4.2 Market Dynamics
      4.2.1 Innovative Therapies to Drive The Market For Acute Lymphocytic Leukemia
      4.2.1.2 Oncology Is The Largest Therapeutic Market With High Unmet Needs
      4.2.2 Market Restraints
         4.2.2.1 Costs Associated With The Treatment
         4.2.2.2 Adverse Events of Treatment
         4.2.2.3 Low Production Capability of Drugs
         4.2.2.4 Genericization of The Major Drugs
      4.2.3 Market Opportunities
      4.2.3.1 Limited Players in The Market
      4.2.3.2 Leukemia's Underserved Patient Populations offer Potential For Market Growth
   4.3 Burning Issues
   4.4 Winning Imperatives
      4.4.1 Market Expansion Through Multiple Therapeutic Approaches
5 Leukemia Product Market
5.1 Market Overview
5.1.1 Hyper-Cvad Regimen
5.1.2 Calgb 8811 Regimen
5.1.3 Linker Regimen
5.1.4 Nucleoside Metabolic Inhibitors (Clolar + Arranon)
5.1.5 Oncaspar

6 Acute Lymphocytic Leukemia Pipeline Molecules (Phase III)
6.1 Introduction
6.1.1 Graspa
6.1.2 Marqibo
6.1.3 Inotuzumab Ozogamicin

7 Geographic Analysis
7.1 Introduction
7.2 U.S.
7.3 Canada
7.4 U.K.
7.5 Germany
7.6 France
7.7 Italy
7.8 Spain
7.9 Japan

8 Company Profiles (Overview, Financials, Products Portfolio, Growth Strategy, and Developments)*
8.1 Erytech Pharma
8.2 Genzyme Corporation
8.3 Talon Therapeutics, Inc. (Spectrum Pharmaceuticals, Inc.)
8.4 Sigma-Tau Pharmaceuticals, Inc.
8.5 Pfizer Inc
8.6 Glaxosmithkline Plc

*Details On Financials, Products Portfolio, Growth Strategy, and Developments Might Not Be Captured in Case of Unlisted Companies.

Competitive Developments (2008 – 2013)
- Acquisitions/Collaborations/Partnerships/ Agreements/Joint Ventures, 2008 – 2013
- New Product Launches, 2008 – 2013
- Expansions/New Facilities/investments, 2008 – 2013
- Approvals, 2008 – 2013
- Developments Related to Clinical Trials, 2008 – 2013
- Other Developments, 2008 – 2013

List Of Tables (50 Tables)
Table 1 Yearly Cost of Drugs in North America & Japan, 2013 ($)
Table 2 Yearly Cost of Drugs in European Countries, 2013 ($)
Table 3 Dosage Pattern of All Drugs
Table 4 Acute Lymphocytic Leukemia Drugs: Patent Status
Table 5 Acute Lymphocytic Leukemia Drugs: Market Revenue, By Type, 2011 – 2020 ($Million)
Table 6 Acute Lymphocytic Leukemia Drugs/Regimens Market Revenue, 2011 – 2020 ($Million)
Table 7 Acute Lymphocytic Leukemia Regimen (Hyper-Cvad) Market Revenue, By Country, 2011 – 2020 ($Million)
Table 8 Acute Lymphocytic Leukemia Regimen (Calgb 8811) Market Revenue, By Country, 2011 – 2020 ($Million)
Table 9 Acute Lymphocytic Leukemia Drugs (Linker Regimen) Market Revenue, By Country, 2011 – 2020 ($Million)
Table 10 Acute Lymphocytic Leukemia Drug Class (Nucleoside Metabolic Inhibitors) Market Revenue, By Country, 2011 – 2020 ($Million)
Table 11 Acute Lymphocytic Leukemia Drugs (Oncaspar) Market Revenue, By Country, 2011 – 2020 ($Million)
List Of Figures (28 Figures)

Figure 1 Acute Lymphocytic Leukemia Market in G8 Countries, By Existing Regimens/Drugs ($Million)
Figure 2 Acute Lymphocytic Leukemia Market in G8 Countries, By Product Pipeline ($Million)
Figure 3 Status of Acute Lymphocytic Leukemia Product Pipeline
Figure 4 Acute Lymphocytic Leukemia Market, By Country
Figure 5 Most Common Types of Leukemia
Figure 6 Total Leukemia Population, By Country, 2008 – 2020
Figure 7 Acute Lymphocytic Leukemia: Age At Diagnosis
Figure 8 Stages and Phases of Acute Lymphocytic Leukemia
Figure 9 Acute Lymphocytic Leukemia: Population, By Country, 2008 – 2020
Ordering:

Order Online - [http://www.researchandmarkets.com/reports/2713355/](http://www.researchandmarkets.com/reports/2713355/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – Pipeline Forecast & Market Forecast in G8 Countries (2011 – 2020)
Web Address: http://www.researchandmarkets.com/reports/2713355/
Office Code: SCH3K93U

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 5650</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 6650</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 8150</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>__________________________</td>
<td>Last Name:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World